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 23 
Running Head: Antibacterial activity and mode of action of toremifene 24 
ABSTRACT 25 
The spread of antibiotic resistance and the challenges associated with antiseptics such as 26 
chlorhexidine have necessitated the search for new antibacterial agents against oral bacterial 27 
pathogens. As a result of failing traditional approaches, drug repurposing has emerged as a 28 
novel paradigm to find new antibacterial agents. In this study, we examined the effect of the 29 
FDA-approved anticancer agent toremifene against oral bacteria Porphyromonas gingivalis 30 
and Streptococcus mutans. We found that the drug was able to inhibit growth of both 31 
pathogens as well as prevent biofilm formation at concentrations ranging from 12.5 to 25 µM. 32 
Moreover, toremifene was shown to eradicate preformed biofilms at concentrations ranging 33 
from 25 to 50 µM. In addition, we found that toremifene prevents P. gingivalis and S. mutans 34 
biofilm formation on titanium surfaces. A time-kill study indicated that toremifene acts 35 
bactericidal against S. mutans. Macromolecular synthesis assays revealed that treatment with 36 
toremifene does not cause preferential inhibition of DNA, RNA, or protein synthesis 37 
pathways, indicating membrane-damaging activity. Biophysical studies using fluorescent 38 
probes and fluorescence microscopy further confirmed the membrane-damaging mode of 39 
action. Taken together, our results suggest that the anti-cancer agent toremifene is a suitable 40 
candidate for further investigation for the development of new treatment strategies for oral 41 
bacterial infections.  42 
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 46 
INTRODUCTION 47 
Oral infections are among the most common diseases worldwide (1). These infections are 48 
typically caused by biofilm-forming bacteria present on the surfaces of both hard and soft 49 
tissues (2). The Gram-negative, anaerobic bacterium Porphyromonas gingivalis and the 50 
Gram-positive bacterium Streptococcus mutans are two important causative agents of oral 51 
infections. P. gingivalis is frequently involved in chronic inflammatory diseases such as 52 
periodontitis and peri-implantitis, resulting in the destruction of soft and hard tissues 53 
surrounding teeth and dental implants, respectively (3, 4). S. mutans is known to be the main 54 
pathogenic agent of dental caries, a chronic disease characterized by irreversible destruction 55 
of the tooth (5).  56 
Treatment of oral infectious diseases frequently involves the use of anti-infective agents such 57 
as chlorhexidine, or in severe cases antibiotics (6, 7). However, the side effects associated 58 
with chlorhexidine, such as teeth staining, calculus formation and change of taste sensation, 59 
and the development of resistance against antibiotics necessitate the search for alternatives (7, 60 
8). Recently, drug repurposing has gained more attention as an alternative strategy to identify 61 
new antimicrobial agents. There are several advantages to repurposing old drugs with known 62 
safety and pharmacokinetic profiles over de novo drug discovery. Examples include a 63 
reduction in time, cost and risks associated with the development of novel antibiotics (9, 10). 64 
In an effort to repurpose existing drugs as antibacterial agents, we recently screened the NIH 65 
clinical library against P. gingivalis. Three compounds were selected that showed potent 66 
activity against P. gingivalis (toremifene, zafirlukast, and N-arachidonoylaminophenol 67 
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(AM404)) (11). The antibacterial activity of toremifene (Figure 1), an FDA-approved drug 68 
used in the treatment of breast cancer (12, 13), was further characterized in this study.  69 
The first aim of this study was to assess the antibacterial and antibiofilm activity of 70 
toremifene against the oral pathogens P. gingivalis and S. mutans. Furthermore, the effect of 71 
toremifene against oral biofilms formed on titanium, a material frequently used for implant 72 
applications, was evaluated. Finally, the antibacterial mode of action of toremifene was 73 
investigated. The findings from this study will provide valuable insight into the potential 74 
therapeutic application of toremifene for the treatment of oral infectious diseases.  75 
 76 
MATERIAL AND METHODS 77 
 78 
Bacterial strains and chemicals 79 
P. gingivalis ATCC 33277 was routinely grown on 5 % horse blood agar supplemented with 80 
hemin (5 µg/ml) and menadione (1 µg/ml) at 37 °C under anaerobic conditions (90 % N2, 5 % 81 
H2 and 5 % CO2) using an Anoxomat AN2OP system (Mart Microbiology, Drachten, the 82 
Netherlands). S. mutans ATCC 25175 was routinely grown on solid trypticase soy agar (TSB, 83 
Becton Dickinson Benelux) containing 1.5 % agar at 37 °C. Liquid cultures of all strains were 84 
grown in TSB. 85 
Toremifene was purchased from TCI EUROPE N.V. and stock solutions of 20 mM were 86 
prepared in dimethyl sulfoxide (DMSO).  87 
 88 
Antibacterial assays 89 
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The minimum inhibitory concentration (MIC) of toremifene was evaluated in TSB as 90 
described before (14). To determine the minimum bactericidal concentration (MBC), 10 µl 91 
aliquots were taken from the wells of the MIC assay that did not show bacterial growth and 92 
were plated onto agar plates. After incubation of the plates, the MBC was determined as the 93 
lowest concentration of toremifene for which no colony forming units (CFUs) were observed.  94 
 95 
Antibiofilm assays 96 
The minimum biofilm inhibitory concentration (MBIC) values of toremifene were determined 97 
using crystal violet staining. P. gingivalis biofilms were grown anaerobically on the 98 
polystyrene pegs of Nunc Immuno-TSP lids (Nunc-Immuno TSP, VWR International) as 99 
described previously, with minor modifications (15). Overnight cultures of P. gingivalis were 100 
diluted 1/10 in TSB. Next, two-fold serial dilutions of toremifene in cell suspension (0 - 200 101 
µM) were prepared at a volume of 150 µl in the polystyrene microtiter plates of the Nunc 102 
Device. Subsequently, the plates were covered with a lid containing the pegs and biofilms 103 
were allowed to grow on the pegs for 72 h at 37 °C, without shaking. After incubation, the 104 
pegs were washed once with phosphate-buffered saline (PBS), stained with 200 µl 0.1 % 105 
crystal violet (wt/vol) in an isopropanol-methanol-PBS solution (1/1/18 [vol/vol]) during 1 h 106 
and washed with water to remove excess stain and air-dried (0.5 h). Next, the remaining 107 
crystal violet stain was removed from the pegs in 200 µl acetic acid (30 %) and the intensity 108 
was measured by determining the OD570, using a Synergy MX multimode reader (Biotek, 109 
Winooski, VT).  110 
S. mutans biofilms were grown on the bottom of the wells of polystyrene microtiter plates, as 111 
they failed to grow on pegs. To this end, overnight cultures were diluted 1/200 in Brain-Heart 112 
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Infusion medium (BHI; Becton Dickinson Benelux) supplemented with 3 % sucrose and two-113 
fold serial dilutions (150 µl) of toremifene in the cell suspensions (0 - 200 µM) were prepared 114 
in the microtiter plate. After 24 h of biofilm formation at 37 °C, biofilm formation was 115 
assessed by crystal violet staining as described above. The lowest concentration of toremifene 116 
required to inhibit biofilm formation was defined as the MBIC.  117 
In addition, the biofilm inhibitory effect of toremifene against S. mutans and P. gingivalis was 118 
tested under shaking conditions. Biofilms were grown and quantified as described above, with 119 
the difference that biofilms were grown in a shaking incubator.  120 
To determine the effect of toremifene on preformed biofilms, 72 h-old (P. gingivalis) or 24 h-121 
old (S. mutans) biofilms were grown on polystyrene surfaces as described above. 122 
Subsequently, the biofilms were treated with 150 µl growth medium containing toremifene (0 123 
- 200 µM) and were incubated at 37 °C for 24 h. Next, the biofilms were washed with PBS 124 
and quantified with cell titre blue (CTB) by adding 200 µl of CTB diluted 1/100 in PBS to 125 
each well. After 24 h of incubation in the dark at 37 °C, fluorescence was measured (λex: 535 126 
nm and λem: 590 nm) using the Synergy MX multimode reader (Biotek, Winooski, VT). The 127 
minimum biofilm reduction concentration (MBRC) was defined as the lowest concentration 128 
of toremifene able to eradicate the preformed biofilm.  129 
 130 
Inhibition of biofilm formation on titanium disks 131 
To evaluate the biofilm inhibitory activity of toremifene against P. gingivalis and S. mutans 132 
biofilms grown on titanium, round titanium disks (commercially pure titanium, grade 2; 133 
height: 2 mm, width: 0.5 cm) were used. Tests with P. gingivalis were performed under 134 
anaerobic conditions. First, bacterial suspensions were prepared by diluting overnight cultures 135 
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of P. gingivalis 1/10 in TSB and of S. mutans 1/200 in BHI medium supplemented with 3 % 136 
sucrose. Next, the titanium disks were placed at the bottom of the wells of a 96-well plate and 137 
were challenged with 200 µl of a bacterial suspension containing 0 to 50 µM toremifene. 138 
After 72 h (P. gingivalis) or 24 h (S. mutans) of incubation at 37 °C under static conditions, 139 
disks were removed from the wells and subsequently washed with PBS to remove non-140 
adherent bacteria and placed in centrifuge tubes containing 1 mL PBS. Adherent bacteria 141 
were removed from the disks by sonication (45,000 Hz in a water bath sonicator (VWR USC 142 
300-T) for 10 min), followed by vortexing (1 min). Bacterial viability was quantified by serial 143 
dilution plating (CFU counts). 144 
In addition, the BacLight LIVE/DEAD bacterial viability staining kit (Molecular Probes, 145 
Invitrogen) was used to microscopically evaluate the viability of the biofilms formed on 146 
titanium disks. After incubation, the disks were washed with 1x PBS and were transferred to a 147 
LIVE/DEAD staining solution containing SYTO 9 and propidium iodide (PI) (prepared 148 
according to manufacturer’s instructions). After 10 min of incubation at room temperature in 149 
the dark, the disks were washed again in 1x PBS and were mounted on a coverslip for 150 
imaging. The stained biofilm cells were visualized under a Zeiss Axio imager Z1 fluorescence 151 
microscope equipped with a EC Plan-Neofluar 20x objective using the SYTO 9 (λex = 483 152 
nm; λem = 500 nm) and PI (λex = 305 nm; λem = 617 nm) channels.  153 
 154 
Time-kill assay 155 
Exponential-phase cells of S. mutans were incubated with 1x and 4x the MIC of toremifene or 156 
chlorhexidine at 37 °C under shaking conditions (see Table S1). At periodic intervals, aliquots 157 
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taken from the samples were serially diluted in MgSO4 and subsequently plated on TSB agar. 158 
After incubation for 2 days as 37 °C, cell viability was determined by CFU counting.  159 
 160 
Single-step resistance selection 161 
The frequency at which mutants of P. gingivalis and S. mutans emerge that are resistant to 162 
antibacterial agents was determined as described previously (16). Briefly, 500 µl of an 163 
overnight culture of P. gingivalis or S. mutans was plated on agar plates containing 164 
antibacterial agents at 5x the MIC (see Table S1). In parallel, the overnight cultures were 165 
serially diluted and plated on non-selective agar. After incubation of the plates for 7 (P. 166 
gingivalis) or 2 (S. mutans) days, the MIC of the antibacterial agents for the surviving 167 
colonies on selective agar was determined to verify resistance. The spontaneous mutation 168 
frequency was calculated by dividing the number of surviving colonies on selective plates by 169 
the total number of colonies on non-selective plates after incubation.  170 
 171 
Macromolecular synthesis assay 172 
The effect of toremifene on the macromolecular synthesis pathways in S. mutans was 173 
determined by monitoring the incorporation of radiolabeled precursors of macromolecules. 174 
Briefly, S. mutans exponential-phase cells (OD595 0.2 to 0.3) were incubated with radiolabeled 175 
precursors for DNA ([3H] thymidine (1 μCi)), RNA ([3H] uridine (2.5 μCi)), and proteins 176 
([3H] leucine (2.5 μCi)). Next, the cells were treated with 4x the MIC of toremifene or control 177 
antibacterials (ciprofloxacin, rifampicin, tetracycline, triclosan; see Table S1). After 10 min 178 
incubation at 37 °C, 100 µl was taken from the samples and was resuspended in 3 ml ice-cold 179 
10 % trichloroacetic acid to stop the reactions and to release free radiolabeled precursors from 180 
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cells. Next, the samples were filtered through Whatman 25-mm GF/C glass microfiber filters 181 
and were washed three times with 3 ml ice-cold water. Subsequently, the dried filters were 182 
transferred to scintillation vials containing 3.5 ml scintillation fluid. Each vial was counted in 183 
a liquid scintillation counter (HIDEX 300 SL) for 2 minutes. The results are expressed as 184 
percentage of incorporation as compared to the untreated control.  185 
 186 
Membrane permeabilization assays 187 
The ability of toremifene to permeabilize the outer membrane of P. gingivalis was determined 188 
using the fluorescent dye N-phenyl-1-napthylamine (NPN, Sigma, USA) as previously 189 
described (16), with some modifications. Briefly, exponential-phase cells were washed and 190 
resuspended to an OD595 of 0.1 in buffer (5 mM HEPES, pH 7.4). Next, toremifene (0 - 25 191 
µM) and NPN (10 µM) were added and changes in fluorescence were recorded after 192 
incubation for 5 minutes using a Synergy MX multimode reader (Biotek, Winooski, VT) (λex: 193 
350 nm and λem: 420 nm). Triclosan at 1x the MIC was used as a positive control because of 194 
its strong outer membrane permeabilizing properties. Ciprofloxacin at 1x the MIC was used 195 
as a negative control (see Table S1).  196 
The ability of toremifene to permeabilize the inner membrane of P. gingivalis and the 197 
membrane of S. mutans was determined using the fluorescent dye SYTOX green (Invitrogen, 198 
USA) as previously described (16). Briefly, exponential-phase cells were washed and 199 
resuspended to an OD595 of 0.5 in PBS. Next, cells were incubated with toremifene (0 - 25 200 
µM) and SYTOX green (1 µM) at 37 °C for 15 min. Thereafter, the increase in fluorescence 201 
was measured using a Synergy MX multimode reader (Biotek, Winooski, VT) (λex: 504 nm 202 
and λem: 523 nm). Melittin (10 µg/ml for P. gingivalis; 2.5 µg/ml S. mutans) was used as a 203 
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positive control because of its strong inner membrane permeabilizing properties. 204 
Ciprofloxacin at 1x the MIC was used as a negative control (see Table S1). 205 
The fluorescent values of each condition were divided by the respective OD595 values to 206 
correct for the cell density of the culture. In addition, this ratio was corrected for background 207 
fluorescence by subtracting fluorescent values of untreated cells.  208 
 209 
BODIPY-TR-cadaverine displacement assay 210 
To determine the ability of toremifene to bind with the lipid A part of lipopolysaccharides 211 
(LPS), the fluorescent probe Bodipy TR cadaverine (BC) (Thermo Fisher Scientific, USA) 212 
was used. In this study, exponential-phase cells of P. gingivalis were washed and resuspended 213 
to an OD595 of 0.3 in PBS. Next, cell suspensions were transferred to the wells of a black 96-214 
well microtiter plate and were mixed with 2.5 µM Bodipy TR cadaverine. After 2 h of 215 
incubation at 37 °C, a 2-fold serial dilution of toremifene (0 - 50 µM) was added to the wells. 216 
Then, fluorescence was assessed for 30 min using a Synergy MX multimode reader (Biotek, 217 
Winooski, VT) (λex: 580 nm and λem: 620 nm). Cells treated with 1x the MIC of ciprofloxacin 218 
were used as a negative control (see Table S1). Cells treated with 1x and 4x the MIC of 219 
chlorhexidine were used as a positive control (see Table S1). BC displacement from LPS was 220 
calculated using the formula ((F – F0)/(Fmax – F0)) × 100, where Fmax is the fluorescence 221 
intensity of BC without cells, F0 is the intensity in the presence of cells alone, and F is the 222 
intensity of the mixture of cells and BC at varying concentrations of toremifene, 223 
chlorhexidine or ciprofloxacin. 224 
 225 
Fluorescence microscopy 226 
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Exponential phase cells of P. gingivalis and S. mutans were treated with 4x the MIC of 227 
toremifene or control antibacterials (ciprofloxacin, rifampicin, tetracycline, triclosan; see 228 
Table S1). After 30 min of incubation at 37 °C, cells were centrifuged and stained with 10 229 
µg/ml N-(3-triethylammoniumpropyl)-4-(p-diethylaminophenyl-hexatrienyl) pyridinium 230 
dibromide (FM 4-64, Molecular Probes) for 10 min at room temperature before being imaged. 231 
Cells were visualized using a Zeiss Axio imager Z1 fluorescence microscope equipped with a 232 
EC Plan-Neofluar 100x objective, using the FM 4-64 channel (λex = 506 nm; λem = 751 nm). 233 
 234 
Hemolysis assay 235 
The test was performed as described previously, with some modifications (17). Briefly, fresh 236 
horse red blood cells (RBCs) were rinsed three times with PBS by centrifugation for 10 min at 237 
800 g and diluted in PBS to achieve a final RBC concentration of 4 %. The resulting 238 
suspension was incubated at 37 °C for 10 min under shaking conditions. Subsequently, 200 µl 239 
of the suspensions were transferred to the wells of a microtiter plate and the assay was 240 
initiated by addition of different concentrations of toremifene to the suspensions. Controls 241 
included RBC suspensions treated with PBS and with triton X-100 (1 %) to provide reference 242 
for 0 % and 100 % hemolysis, respectively. The resulting suspensions were incubated for 60 243 
min at 37 °C.  Following centrifugation for 10 min at 800 g, hemolysis was assessed by 244 
measuring the absorbance of the supernatant at 540 nm. Percentage of hemolysis was 245 
calculated relative to 100% hemolysis with Triton X-100. 246 
 247 
Cytotoxicity assay 248 
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A cytotoxicity test of toremifene was performed on a cell type relevant to the oral cavity 249 
homeostasis, with the aim of screening for concentrations that do not inhibit cell growth or 250 
induce cell death. HOC18 cells, an immortalized human oral gingival epithelial cell line, were 251 
used (18). Cells were plated in 96-well plates at 15000 cells/well in Minimum Essential 252 
Medium Eagle-Alpha Modification (αMEM; Sigma, Bornem, Belgium) with 0.292 g/l l-253 
glutamine (G7513; Sigma, Bornem, Belgium) supplemented with 10 % fetal bovine serum 254 
(PAA Laboratories GmbH, Pasching, Austria) and 1 % antibiotic-antimycotic (Gibco® 255 
15240, Life Technologies SAS, Saint Aubin, France). Cells were maintained overnight at 37 256 
°C in a humidified environment with 5 % CO2.  257 
At day 1 post-seeding, cells were incubated with toremifene by adding the compound to the 258 
culture medium. A two-fold serial dilution assay of toremifene was used, starting from 50 259 
μM. Suspensions of the same cell line under the same conditions exposed to triton X-100 (5 260 
%) or cultured without chemicals were used as controls. The proliferation of the HOC18 cells 261 
in the presence or absence of chemicals was investigated after 1 day of compound addition. 262 
Cell viability was monitored using the XTT assay according to manufacturer instructions 263 
(XTT Cell proliferation Kit II, Roche Diagnostics GmbH, Roche Applied Science, Penzberg, 264 
Germany). Briefly, this is a colorimetric assay, performed by adding XTT solution 4 h prior 265 
the end of toremifene (or triton X-100) exposure. In this assay, metabolically active cells 266 
cleave the yellow tetrazolium salt to form the orange formazan dye, whose absorbance is 267 
recorded at 450 nm and 650 nm (reference wavelength), using a spectrophotometer 268 
(Multiskan Ascent 96/384, Thermo Scientific, Waltham, MA, USA), associated with Ascent 269 
software version 2.6 (Thermo Electron Corporation, P.O. Box 100 FIN-01621, Vantaa, 270 
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Finland). Percentage of cytotoxicity was calculated relative to 100% cytotoxicity with Triton 271 
X-100. 272 
 273 
Statistical analysis and reproducibility of the results 274 
Statistical analysis was performed by one-way ANOVA, followed by Dunnett's multiple 275 
comparison test. p-values < 0.001, < 0.01, and < 0.05 were considered to be statistically 276 
significant. All experiments were repeated at least three times.  277 
 278 
RESULTS 279 
 280 
Antibacterial and antibiofilm activity of toremifene against P. gingivalis and S. mutans 281 
In a previous screening of a drug-repositioning library, the anticancer drug toremifene was 282 
identified as a new antibacterial compound that shows activity against P. gingivalis (11). To 283 
further evaluate the antibacterial potential of toremifene against oral bacteria, its activity was 284 
investigated against the prominent oral pathogens P. gingivalis and S. mutans using MIC, 285 
MBC, MBIC, and MBRC assays. Strikingly, as evidenced from Table 1, the activity of 286 
toremifene against planktonic and biofilm cultures is similar, underlining the antibacterial 287 
potential of this compound.  In addition, we find that toremifene is active against biofilms 288 
grown under shaking conditions.  289 
 290 
Activity of toremifene against P. gingivalis and S. mutans biofilms grown on titanium 291 
disks 292 
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Titanium has a high level of biocompatibility, making it a very suitable implant material for 293 
dental implants (19). Therefore we tested if toremifene remains active against P. gingivalis 294 
and S. mutans biofilms grown on titanium disks. As shown in Figure 2A and B, toremifene 295 
concentrations of 25 and 12.5 µM significantly reduce biofilm formation on titanium disks by 296 
P. gingivalis and S. mutans, respectively. In addition, the LIVE/DEAD bacterial viability kit 297 
was used to visualize the viability of biofilms formed on titanium surfaces (Figure 2C). This 298 
kit contains two dyes: SYTO 9, which stains live bacteria green and PI, which stains bacteria 299 
with compromised membranes. Compared to the untreated disks, a lower number of viable 300 
green cells is detected on the titanium disks incubated from a concentration of 25 µM 301 
toremifene for P. gingivalis and from a concentration of 12.5 µM toremifene for S. mutans, 302 
thereby corroborating the results of the CFU counts. 303 
 310 
Time-kill assay of toremifene and chlorhexidine against S. mutans 311 
To investigate the bactericidal activity of toremifene, and to compare it with the activity of the 312 
commonly used antiseptic chlorhexidine, time-kill assays were performed (Figure 3). For a 313 
number of practical reasons (e.g. sampling at different time points under anaerobic 314 
conditions), we decided to assess the killing kinetics of toremifene against S. mutans instead 315 
of P. gingivalis. A clear bactericidal effect is observed when S. mutans cells are incubated for 316 
24 h at 1x and 4x the MIC of toremifene, as can be seen by a reduction in cell counts by 6.2 317 
log10 CFU/ml and 6.5 log10 CFU/ml, respectively. Chlorhexidine exhibits a much slower 318 
bactericidal activity, with only a reduction in cell counts by 4.8 log10 CFU/ml after 24 h 319 
incubation with 4x the MIC. Regrowth is observed after 24 h incubation with 1x MIC of 320 
chlorhexidine.  321 
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 322 
Single-step resistance selection 323 
For an antibacterial agent to remain effective during treatment, emergence of resistance 324 
should be minimal. For this reason, we attempted to determine the frequency at which 325 
mutants resistant to toremifene appear. However, no spontaneous toremifene-resistant mutants 326 
of S. mutans could be generated (mutation frequency < 4.7 x 10-9). In contrast, rifampicin-327 
resistant mutants of S. mutans were obtained with an average mutation frequency of 1.24 ± 328 
0.9 x 10-8. Similarly, no spontaneous toremifene-resistant mutants of P. gingivalis could be 329 
recovered (mutation frequency < 5.93 x 10-9).  330 
 331 
Effect of toremifene on macromolecular synthesis pathways  332 
The effect of toremifene on three macromolecular synthesis pathways (DNA, RNA, and 333 
protein synthesis) was tested by determining the incorporation of radiolabeled precursors into 334 
macromolecules after short exposure of S. mutans to 4x the MIC of toremifene (Figure 4). 335 
The effect of toremifene on a specific macromolecular synthesis pathway was compared to 336 
the effect after treatment with 4x the MIC of a known inhibitor of this pathway (ciprofloxacin 337 
(DNA synthesis), rifampicin (RNA synthesis), and tetracycline (protein synthesis)). In 338 
addition, negative controls were included in all assays (tetracycline for DNA and RNA 339 
synthesis, ciprofloxacin for protein synthesis). Treatment with toremifene causes a moderate 340 
inhibition of incorporation of precursors into all tested macromolecules and does not result in 341 
a preferential inhibition. These results are typical for treatment of bacterial cells with a 342 
membrane-damaging agent (20–23). Indeed, treatment of the cells with the membrane-343 
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damaging antibacterial agent triclosan causes a similar effect as toremifene on the 344 
incorporation of precursors into macromolecules.  345 
 346 
Effect of toremifene on membrane permeability  347 
To investigate the membrane-damaging effects of toremifene on the outer membrane of P. 348 
gingivalis, the hydrophobic fluorescent probe NPN was used. Normally, NPN cannot partition 349 
into the membrane due to the presence of lipopolysaccharides. However, when the outer 350 
membrane is damaged, NPN can enter the phospholipid layer, which results in increased 351 
fluorescence (24). As shown in Figure 5A, treatment of the bacteria with increasing 352 
concentrations of toremifene results in an increased uptake of NPN in the membrane. These 353 
results indicate that toremifene alters outer membrane permeability. To determine the effect of 354 
toremifene on the inner membrane of P. gingivalis and the membrane of S. mutans, the 355 
nucleic acid stain SYTOX green was used. This stain does not penetrate the inner membrane 356 
of bacteria. However, when the inner membrane is permeabilized, SYTOX green can enter 357 
the cell and bind to nucleic acids, thereby emitting a strong fluorescent signal (25). As seen in 358 
Figure 5B and 5C, SYTOX green uptake is increased with increasing concentrations of 359 
toremifene, indicating that the compound is also capable of permeabilizing the inner 360 
membrane of P. gingivalis and the membrane of S. mutans. 361 
 362 
Binding of toremifene with LPS  363 
Next, we examined the interaction between toremifene and LPS of P. gingivalis, using the 364 
Bodipy TR cadaverine displacement assay. Bodipy TR cadaverine is a fluorescent probe that 365 
strongly binds to the lipid A moiety of LPS. When a compound is added that interacts with 366 
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LPS, Bodipy TR cadaverine is displaced from the complex, which results in increased 367 
fluorescence (26). A fast increase in fluorescent signal is observed after treatment with 368 
different concentrations of toremifene, suggesting that the compound binds with high affinity 369 
(Figure 6). 370 
 371 
Microscopic visualization of membrane damage 372 
To further examine the effect of toremifene on the membrane, fluorescence microscopy was 373 
employed using the membrane stain FM 4-64. Treatment of the cells with solvent control 374 
(DMSO) results in intact homogeneously stained membranes (Figure 7). On the other hand, 375 
treatment of the cells with 4x the MIC of toremifene, results in disrupted membranes (Figure 376 
7). Furthermore, the latter observations are comparable to those obtained after treatment of the 377 
cells with 4x the MIC of triclosan. This phenotype is not observed after treatment of cells 378 
with antibiotics with different modes of action (ciprofloxacin, rifampicin, and tetracycline 379 
(Figure S1)). 380 
 381 
Hemolytic activity and cytotoxicity 382 
Repurposing of existing drugs offers the advantage of known safety and pharmacokinetic 383 
profiles. However, for novel applications, cytotoxicity of these compounds remains to be 384 
investigated. We assessed the hemolytic activity of toremifene against horse red blood cells as 385 
well as its potential cytotoxic effect on a human oral gingival epithelial cell line (HOC18). As 386 
shown in Figure 8A, concentrations of toremifene as high as 100 µM do not cause hemolysis, 387 
indicative of good hemo-compatibility. Conversely, exposure for 24 h to toremifene 388 
concentrations exceeding 25 µM is toxic to HOC18 cells (Figure 8B).  389 
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 390 
DISCUSSION 391 
Known side effects of currently used antiseptics and the rising threat of antibiotic resistance 392 
demonstrate the need for the development of novel therapies to treat oral infections. In an 393 
attempt to identify new drugs with potent activity against the oral pathogen P. gingivalis, we 394 
recently performed a screen of a repurposing library (11). From this screening, toremifene 395 
was withheld for further characterization. Toremifene is an FDA-approved anticancer drug 396 
used in the treatment of breast cancer (12, 13). This compound is known to bind with the 397 
estrogen receptor, thereby interfering with the estrogen-mediated growth stimuli of tumor 398 
cells (13). Earlier studies have already reported the potency of toremifene in other 399 
applications. As such, toremifene has been reported to have antibacterial activity against 400 
Francisella novicida, a model organism of the tularemia-causing pathogen Francisella 401 
tularensis, Staphylococcus aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa 402 
(27, 28). Furthermore, we and others have reported on the antifungal effects of toremifene 403 
(28–30). In addition, toremifene has antiviral activity against Ebola viruses (31). However, to 404 
our knowledge, no data exist on its activity and mode of action against oral bacterial 405 
pathogens. Likewise, no extensive study exists on the antibacterial mode of action of 406 
toremifene.  407 
We report here that toremifene displays potent activity against the prominent oral pathogens 408 
P. gingivalis and S. mutans, making it a potential candidate for use as a new antibacterial 409 
agent. Of note, studying bacterial killing kinetics revealed fast killing by toremifene as 410 
compared to the antiseptic chlorhexidine, which is likely to have a positive effect on treatment 411 
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outcome. Furthermore, we found that toremifene has a low tendency for selection of 412 
spontaneous resistant mutants, adding to its potential as a novel therapeutic.  413 
Understanding the mode of action of toremifene is crucial for its development as a potential 414 
antibacterial agent. To get a first idea about its mode of action, a macromolecular synthesis 415 
assay was conducted. We were unable to perform this assay under strict anaerobic conditions 416 
necessary to avoid physiological changes caused by oxidative stresses in P. gingivalis cells 417 
(32). Therefore, we performed the assay using S. mutans cells for which we found that 418 
toremifene moderately inhibits the synthesis of all tested macromolecules. These data suggest 419 
that toremifene possibly acts by disrupting the integrity of the bacterial membrane (20–23). 420 
Subsequently, we validated that toremifene rapidly permeabilizes the outer and inner 421 
membrane of P. gingivalis and the membrane of S. mutans. In addition, we showed that 422 
toremifene is able to interact with the LPS of the outer membrane of P. gingivalis, which 423 
further confirms a direct interaction of toremifene with bacterial membranes. Finally, we 424 
microscopically visualized the changes in bacterial membrane integrity. Non-homogeneously 425 
stained membranes were observed after treatment of both P. gingivalis and S. mutans with 426 
toremifene. Combined, these results indicate that membrane damage likely is the primary 427 
antibacterial mode of action of toremifene, which is in accordance with previous studies. 428 
Indeed, Dean & van Hoek (2015) demonstrated that toremifene at a concentration of 5 µM 429 
strongly permeabilizes the membrane of the Gram-negative bacteria F. novicida. Furthermore, 430 
Delattin et al. (2014) found that toremifene at a concentration of 12.5 µM induces membrane 431 
permeabilization in C. albicans biofilm cells. However, further work is needed to identify the 432 
molecular mechanisms behind the observed membrane damage.  433 
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Thanks to their potentially rapid bactericidal effects, activity against both growing and 434 
dormant populations and low potential for resistance development, membrane-acting agents 435 
are believed to be good candidates for treating biofilm-related persistent infections (33). 436 
Recently, the activity of toremifene against S. aureus biofilms formed under in vivo 437 
conditions has been described, thereby further highlighting the potential of this compound to 438 
be used in treatment of biofilm-related bacterial infections (28). However, to evaluate the 439 
potential of toremifene for application against oral infections, additional experiments should 440 
be conducted using a relevant in vivo model (34). In addition, special attention should be paid 441 
to the fact that in nature, biofilms often exist of multiple bacterial species, underscoring the 442 
need for investigating the activity of toremifene against mixed-species biofilms formed on 443 
different surfaces (35). 444 
Usually, in treatment of breast cancer, patients receive toremifene orally at a dose of 60 445 
mg/day. Some clinical studies even mention the use of toremifene at a dose of 680 mg/day, 446 
which lies well in the range of recommended antibiotic dosages for treatment of oral 447 
infections (13, 36). Regarding toxicity, toremifene is generally well-tolerated by patients (13). 448 
Most common side effects include hot flushes, sweating, nausea and vaginal discharge, and 449 
serious adverse events are rare (13). This is in accordance with our data showing good hemo-450 
compatibility and limited cytotoxicity. It should be noted that, compared the toxicity assay 451 
conditions, shorter treatments (e.g. in the case of mouthwashes) are likely to be even less 452 
detrimental. These findings further pave the way to repurpose the compound for antibacterial 453 
therapeutic uses. 454 
In conclusion, we demonstrated that the anticancer drug toremifene displays antibacterial 455 
activity against planktonic and biofilm cells of the prominent oral bacterial pathogens P. 456 
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gingivalis and S. mutans. Moreover, we showed that toremifene effectively kills these bacteria 457 
in a rapid manner by damaging the bacterial membrane. Future experiments including in vivo 458 
studies will be necessary to fully reveal the potential of toremifene to be used in the treatment 459 
of oral bacterial infections.  460 
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 FIGURE LEDGENDS 574 
 575 
Figure 1. Structure of toremifene (pKa 8.0). 576 
 577 
Figure 2. Reduction of P. gingivalis (A) and S. mutans (B) biofilm formation on titanium 578 
disks by toremifene. Percentage of biofilm formation in the presence of toremifene relative to 579 
the untreated control. Values are means ± SD of three independent experiments. *p < 0.05, 580 
**p < 0.01, ***p < 0.001 as compared with the untreated control. (C) Fluorescence 581 
microscopy images of biofilms formed on titanium disks. Live cells are stained green, cells 582 
with compromised membranes are stained red. Images were processed with unsharp mask of 583 
Zen 2.0. The scale bars represent 100 µm. 584 
 585 
Figure 3. Time-kill kinetics of toremifene against S. mutans. (A) Exponential-phase cells of 586 
S. mutans were treated with 1x the MIC and 4x the MIC of toremifene (TOR), with 1x the 587 
MIC and 4x the MIC of chlorhexidine (CHX) or with the solvents of the drugs (DMSO and 588 
water, respectively). Samples were taken at 0, 1, 2, 3, 4, 5 and 24 h and CFUs/ml were 589 
determined. All data represent means ± SD from 3 independent experiments. The dotted line 590 
indicates the lower limit of detection.  591 
 592 
Figure 4. Percentage of incorporation of radiolabeled precursors into macromolecules after 593 
treatment of S. mutans with 4x the MIC of toremifene (TOR) or control antibacterials 594 
(ciprofloxacin (CIP), rifampicin (RIF), tetracycline (TET), triclosan (TRI)). Data represent the 595 
means of at least three independent replicates ± SD. 596 
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 597 
Figure 5. Effect of toremifene on membrane permeability. (A) Outer membrane 598 
permeabilization of P. gingivalis after treatment with different concentrations of toremifene, 599 
assessed by quantifying NPN uptake. Cells treated with 1x the MIC of triclosan (TRI) were 600 
used as a positive control (see Table S1). (B) Inner membrane permeabilization of P. 601 
gingivalis after treatment with different concentrations of toremifene, determined by 602 
measuring SYTOX green uptake. Melittin (MEL) (10 µg/ml) was used as a positive control. 603 
(C) Effect of increasing concentrations of toremifene on the membrane permeability of S. 604 
mutans, monitored by the uptake of SYTOX green. Cells treated with melittin (MEL) (2.5 605 
µg/ml) served as a positive control. For both (A), (B), and (C), cells treated with ciprofloxacin 606 
(1x the MIC) served as a negative control. Data represent the means of three independent 607 
replicates ± SD (*p < 0.05, **p < 0.01, ***p < 0.001). 608 
 609 
Figure 6. Determination of the binding affinity of toremifene for LPS of P. gingivalis using 610 
Bodipy TR cadaverine (BC). The concentration-dependent displacement of Bodipy TR 611 
cadaverine from LPS induced by toremifene is shown. Cells treated with 1x and 4x the MIC 612 
of chlorhexidine (CHX) were used as a positive control (see Table S1). Cells treated with 1x 613 
the MIC of ciprofloxacin (CIP) were used as a negative control (see Table S1). Data represent 614 
the means of three independent replicates ± SD. 615 
 616 
Figure 7. Microscopic visualization of toremifene-induced membrane damage using the 617 
lipophilic dye FM4-64. Cells were either treated with DMSO (solvent control) or with 4x the 618 
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MIC of toremifene (TOR) or triclosan (TRI). Scale bars correspond to 2 µm. Images were 619 
processed with unsharp mask of Zen 2.0. 620 
 621 
Figure 8. Effect of toremifene on mammalian cells. (A) Dose-response of the hemolytic 622 
activity of toremifene towards red blood cells. Red blood cells were treated with different 623 
concentrations of toremifene, and its hemolytic activity was determined in comparison with 624 
Triton X-100 (100 % hemolysis) and PBS (0 % hemolysis). Tests were performed in 625 
quadruplicate, and the results are presented as means ± SD. (B) Dose-response of the 626 
cytotoxic activity of toremifene towards HOC18 cells. Cytotoxicity was determined in 627 
comparison with Triton X-100 (positive control) and supplemented αMEM medium (0 % 628 
cytotoxicity). Tests were performed in duplicate, and the results are presented as means ± SD. 629 
 630 
TABLES 631 
 632 
Table 1. MIC, MBC, MBIC, MBRC values of toremifene against oral pathogens1 633 
1Abbreviations: MIC, minimum inhibitory concentration; MBC, minimum bactericidal 634 
concentration; MBIC, minimum biofilm inhibitory concentration; MBRC, minimum biofilm 635 
reduction concentration 636 
* MBIC values determined under shaking conditions 637 
 MIC (µM) MBC (µM) MBIC (µM) MBRC (µM) 
P. gingivalis 12.5 25 12.5 / 12.5* 25 
S. mutans 25 50 25 / 12.5* 50 
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